Applies to influenza virus vaccine, h1n1, inactivated: intramuscular suspension.

General

The most common adverse events were soreness at the injection site lasting less than 2 days, and local pain and swelling.^[Ref]

Local

Very common (10% or more): Soreness at vaccination site lasting under 2 days (64%)

Frequency not reported: Local pain and swelling^[Ref]

Nervous system

Frequency not reported: Headache, Guillain-Barre Syndrome, convulsions, myelitis (including encephalomyelitis and transverse myelitis), facial palsy (Bell's palsy), optic neuritis/neuropathy, brachial neuritis, syncope (shortly after vaccination), dizziness, paresthesia^[Ref]

Hypersensitivity

Postmarketing reports: Anaphylaxis, other allergic/hypersensitivity reactions (including urticaria, angioedema)^[Ref]

Dermatologic

Postmarketing reports: Stevens-Johnson syndrome, pruritus^[Ref]

Respiratory

Postmarketing reports: Dyspnea, pharyngitis, rhinitis^[Ref]

Musculoskeletal

Frequency not reported: Myalgia^[Ref]

Hematologic

Postmarketing reports: Thrombocytopenia, lymphadenopathy^[Ref]

Other

Frequency not reported: Fever, malaise

Postmarketing reports: Pain, asthenia/fatigue, pain in extremities, chest pain^[Ref]

Cardiovascular

Postmarketing reports: Vasculitis, vasodilation/flushing^[Ref]